Company Filing History:
Years Active: 2001
Title: **Aurawan Vongs: Innovating Alzheimer’s Research Through Transgenic Mouse Models**
Introduction
Aurawan Vongs, a talented inventor based in Sewell, NJ, has made significant contributions to Alzheimer’s research through innovative patent work. With a focus on transgenic non-human mammals, his research aims to develop better assay systems to help identify compounds that can effectively modulate the production of human amyloid precursor protein.
Latest Patents
Vongs holds a patent for a transgenic mouse expressing a familial form of human amyloid precursor protein. This patent describes a groundbreaking invention involving transgenic non-human mammals that incorporate a DNA sequence encoding a human amyloid precursor protein FAD variant. Specifically, at amino acid position 717, valine is substituted by isoleucine, allowing these transgenic mice to produce the APP-FAD variant in their brains. The significance of this invention lies in its potential as an assay system for determining compounds that can influence brain production of human amyloid precursor protein.
Career Highlights
Aurawan Vongs is employed at Merck & Company, Inc., a leading global healthcare company committed to improving health and well-being. His work contributes to the development of innovative solutions aimed at addressing critical health issues, including Alzheimer’s disease. Vongs’ dedication and research in the field of biotechnology highlight his commitment to advancing scientific knowledge and therapeutic options.
Collaborations
Throughout his career, Vongs has collaborated with notable coworkers such as Gurparlash Singh and Howard Y Chen. Their collective efforts in research and development serve to enhance the impact of discoveries in the field of Alzheimer’s research and other related areas.
Conclusion
With one patent under his belt and a dedicated career at Merck & Company, Inc., Aurawan Vongs is making notable strides in the landscape of Alzheimer’s research through his innovative work on transgenic mouse models. His contributions are pivotal in developing new assay systems that hold the promise of advancing our understanding of Alzheimer’s disease and paving the way for effective treatments.